Recent Updates
Recently added Catalysts
CLNN

Clene Nanomedicine to Present at Upcoming Investor Conferences

Key Takeaway: SALT LAKE CITY, March 03, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative dise

Full Press Release Details

SALT LAKE CITY, March 03, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that Clene will participate in the following upcoming conferences:
Roth 34th Annual Healthcare Conference, March 14, 2022
Presentation Time: 3:00 pm ET
Oppenheimer 32nd Annual Healthcare Conference, March 15, 2022
Presentation Time: 8:40 am ET
Maxim Group Emerging Growth Conference, March 28, 2022
Presentation Time: 5:00 pm ET
Live audio webcasts will be available for on-demand viewing for the Roth and Oppenheimer Conferences and will be available on the Investors section of the company’s website at www.clene.com. A replay will be available after the events and archived on the website for 90 days.
Erica Fiorini, Ph.D., or David Schull
Managing Director, Westwicke
Last updated: Mar 3, 2022